Skip to main
OKUR

OKUR Stock Forecast & Price Target

OKUR Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OnKure Therapeutics Inc demonstrated a narrower net loss of $1.14 per share in 2Q25, compared to the original estimate of $1.22, indicating improved financial performance. The positive safety profile of its leading candidate, OKI-219, was highlighted, as it was well-tolerated across all dose levels with no severe adverse events reported. This combination of reduced losses and strong clinical trial results supports a constructive outlook on the company's potential to advance in the biopharmaceutical market.

Bears say

OnKure Therapeutics is projecting a significant net loss of $4.56 per share for the full year 2025, a slight improvement from a previous estimate of $4.75 per share, indicating ongoing challenges in achieving profitability. The company faces multiple risks, including potential negative clinical results from their lead asset, OKI-219, delays in advancing their pipeline candidates, and difficulties in obtaining timely regulatory approvals. Additionally, competition in the market and long-term dilution risk compound the uncertainties surrounding the company's financial outlook, presenting significant concerns for investors.

OKUR has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OnKure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OnKure Therapeutics Inc (OKUR) Forecast

Analysts have given OKUR a Buy based on their latest research and market trends.

According to 2 analysts, OKUR has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OnKure Therapeutics Inc (OKUR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.